daVinci Surgical System
Breast Conserving Therapy
Medical, Radiation and Inpatient Services
Intensity Modulated Radiation Therapy (IMRT)
IMRT is an advanced radiation therapy system that delivers greater amounts of radiation doses specifically to a cancerous tumor while limiting the amount of radiation to the surrounding healthy tissue. With IMRT, patients get more effective treatment with less chance of major side effects. IMRT gives us another advanced tool to meet the challenge of treatment of several types of cancers, including cancers of the head & neck and prostate.
With the IMRT software and hardware, the radiation oncologists have a higher level of precision in their treatment of the cancerous tumor than ever before. An extremely complex treatment planning computer system and a specialized mechanical device installed in the linear accelerator to shape or "sculpt" the radiation beams are two required components of the IMRT system.
One of the Lewis and Faye Manderson Cancer Center radiation oncologists prescribes the type and amount of treatment that best suits a particular patient’s needs. They work closely with a highly trained health-care team, including medical physicists, who make sure the accelerator delivers the precise dose of radiation to the precise tumor site.
A dosimetrist plans the treatment with input from the physicians and physicists. A radiation therapist sets up the patient for treatment and runs the linear accelerator that delivers the radiation.
da Vinci Surgical System For Prostate Cancer Treatment
The da Vinci Surgical System allows specially trained physicians to use small incisions to introduce
|The daVinci Surgical System combines computer and robotic technologies to produce robot assisted surgery.
miniaturized instruments into a patient's body. The robotic surgical system at DCH is the state-of-the art robotic technology that extends a physician's capabilities through four-arm robotic surgery, with 3-D, high definition visualization and enhanced magnification. This advanced technology enables new, minimally invasive options for prostate cancer surgical procedures.
Click here to view a video of the da Vinci Surgical System.
The da Vinci system combines computer and robotic technologies to produce robot-assisted surgery. The physician is seated at a console which provides a magnified, high resolution 3-D image of the surgical site. The da Vinci instruments translate precise micro-movements of the physician's hands with six degrees of freedom - essentially super human movements.
The precision of the robotic surgery makes it possible to treat a broader range of conditions using the minimally invasive approach. The potential benefits to a patient should translate into a shorter hospital stay, less blood loss, less postoperative pain and a faster recovery.
The Trilogy and the Clinac iX linear accelerators (LINAC) provide precise and powerful cancer treatment. A LINAC delivers a dose of high-energy X-ray to a tumor.
The Trilogy and the Clinac iX linear accelerators (LINAC) will provide precise and powerful cancer treatment. A LINAC delivers a dose of high-energy X-ray to a tumor.
The accelerators enable the treatment staff to use the latest technologies to give higher doses of radiation delivered with precision to kill tumor cells while significantly reducing doses to normal tissues adjacent to the tumor. For patients, this increased accuracy and power means:
· faster treatments
· greater comfort
· fewer side effects
· the potential for better outcomes
With Trilogy, physicians have the option to treat small tumors using stereotactic radiosurgery (SRS), which is delivered in a single treatment, or stereotactic body radiation therapy (SBRT), which is delivered over a period of a few days. Trilogy can also be used for traditional radiation therapy, which is delivered in daily small doses over a period of weeks.
Trilogy can be used to treat most types of cancer, including:
· breast cancer
· head and neck cancer
· liver cancer
· lung cancer
· pancreatic cancer
· prostate cancer
Trilogy can also be used to target tumors that lie extremely close to critical structures or organs, such as the spinal cord or, in the case of head and neck cancer, the eyes or the salivary glands.
Trilogy also has image-guided radiotherapy (IGRT) capability as does the Clinac iX LINAC. "The image-guided radiotherapy capability complements the cancer center's existing intensity modulated radiation therapy (IMRT) program and enables our clinicians to extend the program to include prostate treatments and introduce respiratory gating techniques to track tumor motion caused by the patient's breathing pattern," Cancer Center Director Amanda Henson said.
IGRT helps the physicians minimize the volume of healthy tissue exposed to the treatment beam, giving them the option of using higher doses when a patient needs them.
An on-board imager (OBI) on the Clinac iX LINAC rotates around a patient to take X-ray images and deliver treatments from virtually any angle. Basically this helps the physician choose the best treatment option and exact doses in real time.
RapidArc™ radiotherapy technology is a new form of image-guided, intensity-modulated radiation therapy (IMRT). Image guidance improves tumor targeting, and IMRT shapes the radiation dose so that it conforms closely to the three-dimensional shape of the tumor. This means more dose to the tumor, and less to surrounding healthy tissue. Click here for more details.
Breast Conserving Therapy
Breast Conserving Therapy is considered removal of the tumor or some of the breast tissue less than a mastectomy, which is the removal of the breast. The rate of breast conserving therapy performed at the Manderson Cancer Center very closely mirrors regional and national rates.
In 2006, there were 176 cases of female breast cancer reviewed at the Manderson Cancer Center. The median age at diagnosis was 60. Of the 176 patients studied, 153 cases were evaluated for breast-conserving surgery. Twenty-three patients were excluded for various reasons.
Of these patients, 60 percent were treated with breast-conserving therapy, and 40 percent were treated with non-conserving breast therapy. This compares favorably with the 2004 data provided by the National Cancer Data Base (NCDB), which indicates an average of 52 percent breast conserving therapy in the Alabama Statewide Cancer Registry (ASCR), an average of 53 percent breast conserving therapy in the Southeast region of the United States and a 63 percent breast conserving therapy rate from the entire United States.
When breast cancers are detected and diagnosed early, when the cancer is localized, the relative five-year survival rate is approximately 98 percent. Mammograms are crucial in detecting early-stage breast cancer. Sixty percent of Alabama females of the appropriate age have had a mammogram in the past year, compared to 58 percent of US females.